Aroxybutynin and atomoxetine are a novel oral treatment for obstructive sleep apnea, according to the phase 2b MARIPOSA trial.

Published Date: 26 May 2023

USA: The MARIPOSA Phase 2b trial, which evaluated the dosage needs and safety of the oral drug AD109 (aroxybutynin + atomoxetine).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.

2.

New policy review highlights the importance of health-related quality of life in advanced cancer

3.

In myelofibrosis, combinations of rufolitinib reduce spleen volume.

4.

Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities

5.

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot